Please assess the completion status of the following clinical trial:

Trial Title: A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A histologic diagnosis of malignancy;~* At planned initiation of a new systemic chemotherapy regimen (including patients starting on first chemotherapy or patients previously treated but starting on a new regimen);~* A risk score for VTE ≥3 \[assign score of 2 for very high risk sites of cancer (stomach, pancreas), score of 1 for high risk site (lung, lymphoma, gynecologic, bladder, testicular) and score of 0 for all other sites\], hemoglobin \<10 g/dL or planned use of erythropoiesis stimulating agents, platelet count ≥350,000/mm3, total leukocyte count \> 11,000/mm3 or body mass index ≥ 35 kg/m2\]. Any counts meeting criteria drawn within 2 weeks prior to enrollment are considered acceptable.~* Age 18 years or older~* Provide written, informed consent.~Exclusion Criteria:~* Active bleeding or at high risk of serious bleeding complication in the opinion of the investigator~* Diagnosis of primary brain tumor multiple myeloma, leukemia, or myelodysplastic syndrome~* Planned stem cell transplant~* Life expectancy \< 6 months~* Known allergy to heparin or LMWH~* Patient or caregiver incapable of daily self-injection~* Acute or chronic renal insufficiency with creatinine clearance \< 30 mL/min~* History of heparin-induced thrombocytopenia~* Allergy to contrast agents~* Pregnancy~* Need for anticoagulant therapy~* Platelet count \< 75,000/mm3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High Risk for VTE recieving dalteparin (Type: EXPERIMENTAL): Patients assigned at random to receive prophylactic dalteparin injections
- High Risk for VTE No therapy (Type: NO_INTERVENTION): No prophylactic therapy for VTE prevention given (Subjects receiving standard of care)
- Low Risk for VTE (Type: NO_INTERVENTION): Used as a control for the secondary outcome of evaluating tissue factor in collected blood samples

Based on this trial design, predict the completion outcome and termination type (if applicable).